The landscape of research peptides for weight loss is dominated by GLP-1 receptor agonists — semaglutide, tirzepatide, and retatrutide — which have produced the most significant pharmacological weight loss ever documented in clinical trials.
How Weight Loss Peptides Work
GLP-1 receptor agonists act on hypothalamic GLP-1 receptors to reduce food reward signaling and increase satiety. STEP-1 participants reported 40% reduction in hunger scores vs placebo at the 2.4mg semaglutide dose.
Weight Loss Peptides: Compound-Specific Guides
Each compound has a dedicated dosing guide with titration schedules, side effect management, and protocol recommendations — from semaglutide through retatrutide.
Clinical Trial Weight Loss Data
Randomized controlled trial data: semaglutide STEP-1 (14.9% mean reduction), tirzepatide SURMOUNT-1 (22.5%), retatrutide Phase 2 (24.2% at 12mg dose). All vs placebo over 68–72 weeks.